Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017

Details for Mechanism ID: 17522
Country/Region: Burundi
Year: 2016
Main Partner: Population Services International
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USDOD
Total Funding: $666,921 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $938
Care: TB/HIV (HVTB) $973
Laboratory Infrastructure (HLAB) $150,000
Testing: HIV Testing and Counseling (HVCT) $135,377
Sexual Prevention: Other Sexual Prevention (HVOP) $361,152
Treatment: Adult Treatment (HTXS) $18,481
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 7
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 64
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 3,252
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 12,754
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 16,077
HTS_TST Service Delivery Point (Community): Mobile testing 2017 8,038
HTS_TST Service Delivery Point (Facility): VCT 2017 8,038
HTS_TST Sum of Aggregated Age/Sex <15 2017 71
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 16,006
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 16,077
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 68
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 273
PP_PREV Aggregated Age/sex: 15+ Female 2017 3,385
PP_PREV Aggregated Age/sex: 15+ Male 2017 19,187
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 22,572
PP_PREV Total number of people in the target population 2017 53,700
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 50
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 13
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 38
TB_SCREENDX Screen Results: Screened Positive for TB 2017 57
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 7
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 4
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 103
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 164
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 278
TX_CURR Aggregated Age/Sex: <15 Female 2017 1
TX_CURR Aggregated Age/Sex: <15 Male 2017 1
TX_CURR Aggregated Age/Sex: 15+ Female 2017 54
TX_CURR Aggregated Age/Sex: 15+ Male 2017 197
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 253
TX_CURR Sum of Aggregated Age/Sex <15 2017 2
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 251
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 253
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 5
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 48
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 53
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 53
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 12
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 43
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 53
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 16
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 35
Cross Cutting Budget Categories and Known Amounts Total: $51,692
Gender: Gender Based Violence (GBV) $25,846
GBV Prevention
Implementation
Capacity building
Gender: Gender Equality $25,846
Changing harmful gender norms and promoting positive gender norms
Implementation
Capacity building
Increase gender-equitable access to income and productive resources, including education
Implementation
Capacity building
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building